Drug Detail:Secukinumab (Secukinumab)
Drug Class: Interleukin inhibitors
Usual Adult Dose for Plaque Psoriasis
300 mg subcutaneously at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks (each 300 mg dose is given as 2 subcutaneous injections of 150 mg); for some patients, a dose of 150 mg subcutaneously may be acceptable
Use: Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
Usual Adult Dose for Psoriatic Arthritis
WITH A LOADING DOSE: 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
WITHOUT A LOADING DOSE: 150 mg subcutaneously every 4 weeks; if the patient continues to have active psoriatic arthritis, consider increasing the dose to 300 mg subcutaneously every 4 weeks
Comments:
- For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosage for plaque psoriasis.
- This drug may be administered with or without methotrexate.
Use: Active psoriatic arthritis
Usual Adult Dose for Ankylosing Spondylitis
WITH A LOADING DOSE: 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
WITHOUT A LOADING DOSE: 150 mg subcutaneously every 4 weeks
Uses:
- For active ankylosing spondylitis
- For the treatment of active non-radiographic axial spondyloarthritis (nraxSpA) with objective signs of inflammation
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
- Hypersensitivity to the active component or any of the ingredients
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Each injection should be administered at a different anatomic location (such as upper arms, thighs, or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis.
- This drug is intended for use under the supervision of a physician. Patients may self-inject after proper training in subcutaneous injection technique using the Sensoready pen or prefilled syringe.
- The lyophilized powder for reconstitution is for healthcare provider use only.
Reconstitution/preparation techniques:
- The lyophilized powder should be prepared and reconstituted with sterile water for injection using aseptic technique and without interruption.
- The preparation time from piercing the stopper until end of reconstitution on average takes 20 minutes and should not exceed 90 minutes.
- Refer to the manufacturer product information.
Storage requirements:
- Sensoready pens, prefilled syringes, and vials should be refrigerated at 2C to 8C (36F to 46F).
- Keep the product in the original carton to protect from light until the time of use. -Do not freeze.
- To avoid foaming do not shake.
- This drug does not contain a preservative; discard any unused portion.
General:
- Evaluate patients for tuberculosis (TB) infection prior to initiating this drug.
Patient advice:
- Read the patient leaflet thoroughly before use.
- The Sensoready Pens contain latex.
- The Sensoready Pens should not be shaken.
Frequently asked questions
- What are the new drugs for the treatment of plaque psoriasis?
- Cosentyx vs Humira: How do they compare?
- How long does Cosentyx take to work?
- How and where do you inject Cosentyx?
- Can I get a flu shot while taking Cosentyx?
- Is Cosentyx a biologic / immunosuppressant?
- Does Cosentyx treat Rheumatoid Arthritis?
- Does Cosentyx have a black box warning?